Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The gene regulation landscape of MITF in lung adenocarcinoma

ABSTRACT: The gene regulation landscape of MITF in lung adenocarcinoma

PROVIDER: PRJNA612215 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The gene regulation landscape of MITF in lung adenocarcinoma

Project description:MITF is a transcription factor and identified as a oncoprotein in melanoma, but its role in lung adenoacrcinoma is still unknown. This study sought to investigate the effects of MITF on the biological behavior and global gene expression profiles in lung adenocacinoma cells. We used expression microarrays to identify the global gene alterations in lung adenocacinoma cell line, CL1-0 cells after ectopic expressing three shRNA for knockdown MITF expression.

2023-03-12 | GSE146868 | GEO

The gene regulation landscape of MTAP in lung adenocarcinoma

Project description:The gene regulation landscape of MTAP in lung adenocarcinoma

| PRJNA673435 | ENA

The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

Project description:The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma

| PRJNA1098849 | ENA

Contextual epigenetic regulation of lung adenocarcinoma by GATA6

Project description:Contextual epigenetic regulation of lung adenocarcinoma by GATA6

| PRJNA512628 | ENA

The single cell transcriptional landscape of lung adenocarcinoma metastasis

Project description:The single cell transcriptional landscape of lung adenocarcinoma metastasis

| PRJNA510249 | ENA

Fully accessible fitness landscape of oncogene negative lung adenocarcinoma

Project description:Fully accessible fitness landscape of oncogene negative lung adenocarcinoma

| PRJNA927274 | ENA

Ito2019 - gefitnib resistance of lung adenocarcinoma caused by MET amplification

Project description:The model is based on publication: Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification Abstract: Gefitinib, one of the tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR), is effective for treating lung adenocarcinoma harboring EGFR mutation; but later, most cases acquire a resistance to gefitinib. One of the mechanisms conferring gefitinib resistance to lung adenocarcinoma is the amplification of the MET gene, which is observed in 5–22% of gefitinib-resistant tumors. A previous study suggested that MET amplification could cause gefitinib resistance by driving ErbB3-dependent activation of the PI3K pathway. In this study, we built a mathematical model of gefitinib resistance caused by MET amplification using lung adenocarcinoma HCC827-GR (gefitinib resistant) cells. The molecular reactions involved in gefitinib resistance consisted of dimerization and phosphorylation of three molecules, EGFR, ErbB3, and MET were described by a series of ordinary differential equations. To perform a computer simulation, we quantified each molecule on the cell surface using flow cytometry and estimated unknown parameters by dimensional analysis. Our simulation showed that the number of active ErbB3 molecules is around a hundred-fold smaller than that of active MET molecules. Limited contribution of ErbB3 in gefitinib resistance by MET amplification is also demonstrated using HCC827-GR cells in culture experiments. Our mathematical model provides a quantitative understanding of the molecular reactions underlying drug resistance.

2024-09-02 | BIOMD0000000827 | BioModels

Lung Adenocarcinoma (A549) Immunopeptidomics

Project description:Alterations in cellular antigen processing and presenting machinery has gained increased interest as a hallmark of cancer-related inflammation. Growing evidence suggest that proteasome composition and immunoproteasome expression can influence antigen processing. By performing immunopeptidomics on A549 lung adenocarcinoma cell line following depletion of proteasome regulator PSME4 we identified alterations in the antigenic landscape resulting from changes in proteasome processing.

2023-03-30 | PXD028364 | Pride

Lung Adenocarcinoma (A549) Immunopeptidomics

2023-03-30 | PXD037365 | Pride

The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma [RIP-seq]

Project description:The N6-methyladenosine Epitranscriptomic Landscape of Lung Adenocarcinoma [RIP-seq]

| PRJNA1098859 | ENA